Cantor Fitzgerald Estimates Exagen FY2026 Earnings

Exagen Inc. (NASDAQ:XGN - Free Report) - Equities researchers at Cantor Fitzgerald issued their FY2026 earnings per share estimates for shares of Exagen in a report issued on Wednesday, June 11th. Cantor Fitzgerald analyst R. Osborn expects that the company will earn ($0.31) per share for the year. Cantor Fitzgerald has a "Overweight" rating and a $7.00 price target on the stock. The consensus estimate for Exagen's current full-year earnings is ($0.88) per share.

Several other equities research analysts have also issued reports on XGN. UBS Group reaffirmed an "overweight" rating on shares of Exagen in a research note on Thursday, May 15th. William Blair restated an "outperform" rating on shares of Exagen in a research report on Wednesday, March 12th. Canaccord Genuity Group increased their price target on shares of Exagen from $7.00 to $8.00 and gave the company a "buy" rating in a research report on Tuesday, May 13th. Finally, BTIG Research reissued a "buy" rating on shares of Exagen in a research note on Wednesday, May 7th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of "Buy" and an average price target of $7.50.

Exagen Price Performance

NASDAQ:XGN traded up $0.14 during midday trading on Friday, hitting $7.12. The company had a trading volume of 377,638 shares, compared to its average volume of 123,805. The company has a market capitalization of $151.66 million, a PE ratio of -7.57 and a beta of 1.60. The company has a quick ratio of 4.05, a current ratio of 4.05 and a debt-to-equity ratio of 1.54. Exagen has a 52-week low of $1.71 and a 52-week high of $7.56. The stock's fifty day moving average price is $5.94 and its 200-day moving average price is $4.71.

Exagen (NASDAQ:XGN - Get Free Report) last issued its quarterly earnings data on Monday, May 12th. The company reported ($0.20) EPS for the quarter, meeting the consensus estimate of ($0.20). Exagen had a negative net margin of 30.36% and a negative return on equity of 92.58%. The company had revenue of $15.50 million during the quarter, compared to analysts' expectations of $14.55 million. During the same quarter in the previous year, the company earned ($0.19) earnings per share.

Hedge Funds Weigh In On Exagen

Large investors have recently bought and sold shares of the stock. Northern Trust Corp grew its holdings in Exagen by 16.7% in the 4th quarter. Northern Trust Corp now owns 18,375 shares of the company's stock worth $75,000 after acquiring an additional 2,630 shares during the last quarter. Virtu Financial LLC bought a new stake in shares of Exagen in the fourth quarter worth about $46,000. Corient Private Wealth LLC purchased a new position in Exagen during the 4th quarter valued at about $45,000. Toronto Dominion Bank purchased a new position in Exagen during the 4th quarter valued at about $3,655,000. Finally, Marshall Wace LLP bought a new position in Exagen during the 4th quarter valued at approximately $66,000. 75.25% of the stock is owned by hedge funds and other institutional investors.

Exagen Company Profile

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).